Online citations, reference lists, and bibliographies.
← Back to Search

Epidemiology Of Antituberculosis Drug Resistance 2002–07: An Updated Analysis Of The Global Project On Anti-Tuberculosis Drug Resistance Surveillance

A. Wright, M. Zignol, A. Deun, D. Falzon, for the Global Project on Anti-Tuberculosis Drug Resis Surveillance
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND The Global Project on Anti-Tuberculosis Drug Resistance has been gathering data since 1994. This study provides the latest data on the extent of drug resistance worldwide. METHODS Data for drug susceptibility were gathered from 90 726 patients in 83 countries and territories between 2002 and 2007. Standardised collection of results enabled comparison both between and within countries. Where possible, data for HIV status and resistance to second-line drugs were also obtained. Laboratory data were quality assured by the Supranational Tuberculosis Reference Laboratory Network. FINDINGS The median prevalence of resistance to any drug in new cases of tuberculosis was 11.1% (IQR 7.0-22.3). The prevalence of multidrug resistance in new tuberculosis cases ranged from 0% in eight countries to 7% in two provinces in China, 11.1% in Northern Mariana Islands (although reporting only two cases), and between 6.8% and 22.3% in nine countries of the former Soviet Union, including 19.4% in Moldova and 22.3% in Baku, Azerbaijan (median for countries surveyed 1.6%, IQR 0.6-3.9). Trend analysis showed that between 1994 and 2007, the prevalence of multidrug-resistant (MDR) tuberculosis in new cases increased substantially in South Korea and in Tomsk Oblast and Orel Oblast, Russia, but was stable in Estonia and Latvia. The prevalence of MDR tuberculosis in all tuberculosis cases decreased in Hong Kong and the USA. 37 countries and territories reported representative data on extensively drug-resistant (XDR) tuberculosis. Five countries, all from the former Soviet Union, reported 25 cases or more of XDR tuberculosis each, with prevalence among MDR-tuberculosis cases ranging between 6.6% and 23.7%. INTERPRETATION MDR tuberculosis remains a threat to tuberculosis control in provinces in China and countries of the former Soviet Union. Data on drug resistance are unavailable in many countries, especially in Africa, emphasising the need to develop easier methods for surveillance of resistance in tuberculosis. FUNDING Global Project: United States Agency for International Development and Eli Lilly and Company. Drug resistance surveys: national tuberculosis programmes, the Government of the Netherlands, the Global Fund to Fight AIDS, Tuberculosis and Malaria, Japan International Cooperation Agency, and Kreditanstalt für Wiederaufbau.
This paper references
10.1164/rccm.200709-1436OC
Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa.
M. Barnard (2008)
Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998.
A. Laszlo (2002)
Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing.
A. Laszlo (1997)
MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.
G. Canetti (1963)
Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.
G. Canetti (1969)
BACTEC 460TB system
S. Siddiqi (1996)
The Global Plan to Stop TB, 2006-2015. actions for life: towards a world free of tuberculosis.
Stop Tb Partnership (2006)
Global tuberculosis control: surveillance planning financing. WHO report 2008.
C. Dye (2003)
10.1016/S8756-3452(08)70748-5
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis
L. Tanoue (2008)
10.1086/505877
Global incidence of multidrug-resistant tuberculosis.
M. Zignol (2006)
10.1164/rccm.200801-175PP
Challenges in estimating the total burden of drug-resistant tuberculosis.
T. Cohen (2008)
10.1201/B13468-36
The Global Plan to Stop TB, 2006-2015.
M. Raviglione (2006)
10.1128/JCM.44.3.688-692.2006
Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials
S. Rüsch-Gerdes (2006)
10.1086/518665
HIV infection and multidrug-resistant tuberculosis: the perfect storm.
C. Wells (2007)



This paper is referenced by
Treatment Outcomes Mutations and Their Effect on Tuberculosis Epidemiology of Isoniazid Resistance
Dick van Soolingen (2013)
10.1586/erp.12.5
Economic analyses of diagnostics for tuberculosis: what’s the point?
D. Dowdy (2012)
10.14260/JEMDS/2017/1373
DETECTION OF ACQUIRED MULTIDRUG-RESISTANT TUBERCULOSIS AND EXTENSIVELY DRUGRESISTANT TUBERCULOSIS IN AND AROUND KOLKATA IN RECENT PAST
P. BattacharyaC (2017)
10.1016/j.ccm.2009.08.019
Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children.
H. S. Schaaf (2009)
10.4269/ajtmh.2011.10-0363
Drug resistance surveillance in resource-poor settings: current methods and considerations for TB, HIV, and malaria.
B. Hedt (2011)
10.1128/AAC.02403-12
Epidemiology of Antituberculosis Drug Resistance in Saudi Arabia: Findings of the First National Survey
S. Al-Hajoj (2013)
10.1016/S0140-6736(10)60410-2
Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis
N. Gandhi (2010)
10.1007/s40495-018-0154-1
Safety and Disease Evolution of Fixed-Dose Combination of Antitubercular Treatment Compared to Separate-Drugs Preparation in Extra-Pulmonary Tuberculosis
H. Ayed (2018)
10.1186/1471-2164-16-S2-S14
Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility
Chakshu Vats (2015)
EVALUATION OF THE GENOTYPE MTBDRPLUS ASSAY FOR RIFAMPIN AND ISONIAZID SUSCEPTIBILITY TESTING OF MYCOBACTERIUM TUBERCULOSIS STRAINS IN SPUTUM SPECIME
Sita Ram Sapkota (2016)
10.1038/srep41486
Rapid Sputum Multiplex Detection of the M. tuberculosis Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS
Kang-Yi Su (2017)
10.1016/j.eimc.2011.04.002
Changes in the epidemiology of tuberculosis: the influence of international migration flows.
J. Fortun (2011)
10.1186/1471-2334-10-149
Validation of the GenoType® MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam
M. N. Huyen (2010)
10.1183/09031936.00175812
Multidrug-resistant tuberculosis in children: evidence from global surveillance
M. Zignol (2012)
10.1016/j.vaccine.2011.04.027
Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.
A. Obregón-Henao (2011)
10.1186/1756-0500-4-123
First report of molecular detection of fluoroquinolone resistance-associated gyrA mutations in multidrug-resistant clinical Mycobacterium tuberculosis isolates in Kuwait
N. Al-Mutairi (2010)
10.1007/s10096-010-1125-6
Contribution of rural-to-urban migration in the prevalence of drug resistant tuberculosis in China
W. Wang (2010)
Extensively drug-resistant Mycobacterium tuberculosis: what are these bugs up to in India?
K. Dheda (2009)
10.2174/1874285801408010001
A Retrospective Analysis of Isoniazid-Monoresistant Tuberculosis: Among Iranian Pulmonary Tuberculosis Patients
M. Varahram (2013)
Variations in the occurrence of specific rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from patients of different ethnic groups in Kuwait
S. Ahmad (2012)
10.1016/S2222-1808(12)60075-9
Molecular typing of Mycobacterium tuberculosis isolates from Yaoundé reveals RIF resistance markers, clonal relatedness and mutation patterns
Tedom (2012)
10.1128/AAC.00077-13
Epidemiology of Isoniazid Resistance Mutations and Their Effect on Tuberculosis Treatment Outcomes
M. N. Huyen (2013)
10.1016/S0140-6736(10)60483-7
Tuberculosis control and elimination 2010–50: cure, care, and social development
K. Lönnroth (2010)
10.1016/j.jinf.2012.06.007
Genomic sequence based scanning for drug resistance-associated mutations and evolutionary analysis of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis.
C. Liu (2012)
10.1007/978-3-030-18690-6_20
Bovine Tuberculosis in the Republic of Sudan: A Critical Review
Z. A. Ishag (2019)
10.20546/ijcmas.2019.810.118
Detection of Pre-extensively Drug Resistance (PRE-XDR TB) and Extensively Drug Resistance (XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) Patient by Line Probe Assay
Hiral A Gadhavi (2019)
Design, Synthesis, Characterization and Biological Evaluation of Some Novel Pyridine Derivatives as Anti-Tubercular Agents against INHA
S. S. Kumar (2018)
Innate Immune Responses in (Myco) Bacterial Meningitis
G. Well (2012)
Capture and Characterization of Dioxygen Reactive Intermediates in CYP51Catalysis
Gareth Jennings (2012)
The challenge of drug resistant tuberculosis
Giovanni Satta (2018)
10.1186/1471-2458-9-211
High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India
D. D'souza (2009)
10.5772/54882
Epidemiology of Multidrug Resistant Tuberculosis (MDR-TB)
D. Magana-Arachchi (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar